Adverse Radiation Effects

1.The dominant late toxicity of cranial radiosurgery

Radiation necrosis is the most consequential late effect of cranial SRS. It typically declares itself 6–18 months after treatment (sometimes later), as a focally enhancing, edematous lesion at the treated site. The strongest dosimetric predictor is the volume of normal brain receiving ≥12 Gy (V12Gy); risk climbs steeply as V12 rises, which is why staged or fractionated SRS is used for larger targets. Prior whole-brain radiotherapy, re-irradiation, larger target volume, and concurrent systemic agents all raise the risk. Reported symptomatic rates are on the order of 5–15%, higher for large lesions and re-treatment.

2.The central diagnostic problem

A new or enlarging enhancing lesion after SRS for a metastasis or glioma may be necrosis or recurrent tumor — and the two look alike on conventional MRI. Distinguishing them changes management entirely, so it leans on advanced imaging:

• MR perfusion (DSC, relative cerebral blood volume): rCBV is higher in recurrent tumor and lower in necrosis; a meta-analysis found significantly higher rCBV in recurrence, with an optimal max-rCBV cutoff around 1.8–2.1 relative to normal tissue.
• MR spectroscopy: elevated choline and Cho/NAA and Cho/Cr ratios favor tumor; necrosis shows a depressed, disorganized spectrum.
• Amino-acid PET (FET, FDOPA, MET) and, for some pathologies, DOTATATE: increased uptake favors viable tumor.
• Serial MRI with a growth-then-plateau-then-regression pattern favors necrosis; relentless progression favors tumor.
• Biopsy / resection remains the arbiter when imaging is equivocal and the answer drives therapy — and frequently the specimen shows a mix of both.

3.A stepwise ladder, with practical dosing

Treatment is matched to symptoms and mass effect. Asymptomatic imaging change is observed; symptomatic edema or necrosis is treated, escalating from steroids through anti-VEGF therapy to procedures.

• Observation — for asymptomatic imaging change; most early post-SRS enhancement/edema is followed, not treated.
• Corticosteroids (dexamethasone) — first line for symptomatic edema. A common start is 4 mg twice daily (more, e.g., 4 mg every 6 hours, for significant mass effect), titrated to symptoms and then tapered slowly over weeks; cover with a proton-pump inhibitor and monitor glucose. Effective but limited by cushingoid and metabolic morbidity on prolonged use.
• Bevacizumab — anti-VEGF therapy with Class I evidence from a small randomized, double-blind, placebo-controlled trial in which every treated patient improved radiographically and neurologically and no placebo patient did. A practical regimen is 7.5 mg/kg IV every 3 weeks for ~4 doses (5 mg/kg every 2 weeks is also used); watch for hypertension, proteinuria, thromboembolism, bleeding, and impaired wound healing. The most evidence-based pharmacologic option for steroid-refractory necrosis.
• Boswellia serrata (boswellic acids) — an oral, steroid-sparing anti-edema adjunct. In a randomized, placebo-controlled trial during brain radiotherapy, 4200 mg/day produced a >75% reduction of cerebral edema in ~60% of patients versus ~26% on placebo; it is increasingly used for radiation-induced edema and necrosis, typically ~3600–4500 mg/day in divided doses (gastrointestinal upset is the main limit).
• Pentoxifylline + vitamin E — an antifibrotic/antioxidant combination, commonly pentoxifylline 400 mg 2–3×/day + vitamin E 400–1000 IU/day over months; adding clodronate is the “PENTOCLO” regimen. Weaker evidence, used as an adjunct.
• Hyperbaric oxygen — roughly 20–40 sessions at 2.0–2.4 ATA; variable evidence, mainly for refractory cases.
• LITT (laser interstitial thermal therapy) — minimally invasive cytoreduction for focal, surgically accessible necrosis, and a route to tissue diagnosis.
• Surgical resection — for refractory symptoms, significant mass effect, or diagnostic uncertainty; definitively relieves the lesion and yields tissue.

4.Adverse radiation effects after AVM radiosurgery

After AVM SRS, post-radiosurgery imaging changes (perinidal T2/FLAIR signal and enhancement) are common — radiologically in roughly a third of patients — but symptomatic in a smaller minority (on the order of 10%), usually transient and steroid-responsive. Late cyst formation and chronic encapsulated hematoma are recognized delayed effects years out. These are distinct from the latency-period hemorrhage risk — the AVM can still bleed until obliteration is achieved — which is a feature of the unobliterated nidus, not a radiation injury.

5.Radiation-induced optic neuropathy, hypopituitarism, myelopathy

• Radiation-induced optic neuropathy (RION): painless, often sudden visual loss, typically months to ~3 years out and frequently irreversible. It is constraint-driven and largely preventable: keep the optic apparatus maximum point dose below ~8 Gy in a single fraction, where risk is negligible; risk remains low (on the order of ~1%) up to ~10–12 Gy and rises steeply above that. There is no reliable treatment once it occurs — corticosteroids, anticoagulation, bevacizumab, and hyperbaric oxygen have all been tried with limited success — so prevention by constraint is paramount, and prior radiation lowers tolerance.
• Hypopituitarism after sellar/parasellar SRS develops gradually, accruing to a long-term incidence commonly cited around 20–40% by 10 years (higher with greater stalk and gland dose). The growth-hormone and gonadal axes tend to fail earliest, followed by ACTH and TSH; lifelong annual endocrine screening is required, and keeping dose to the pituitary stalk and gland as low as feasible reduces risk.
• Radiation myelopathy after spine SBRT is rare (well under 1% when cord constraints are respected) but catastrophic and usually irreversible, presenting as a delayed (months–years) myelopathy. Cumulative cord dose governs the reirradiation setting, where limits tighten and prior dose must be accounted for. As with RION, there is no reliable treatment, so the constraint is non-negotiable.

6.Vertebral compression fracture, pain flare, cranial neuropathy

• Vertebral compression fracture (VCF): the signature late effect of spine SBRT (~10–15%), with risk rising for lytic lesions, pre-existing deformity/kyphosis, higher dose per fraction (e.g., ≥ 20 Gy single fraction), and a high SINS. Painful fractures are managed with cement augmentation (vertebroplasty or kyphoplasty); instability or deformity needs surgical stabilization. A high SINS up front should prompt consideration of prophylactic stabilization before, or instead of, ablative single-fraction dosing.
• Pain flare: a transient post-treatment pain increase affecting a substantial minority after spine SBRT, usually within days. It is mitigated by prophylactic dexamethasone — a common regimen is 4 mg daily started on the first treatment day and continued ~4–5 days (some use 8 mg); breakthrough flare is treated with a short steroid course.
• Cranial neuropathy: after vestibular schwannoma SRS, transient trigeminal or facial dysfunction and dose-dependent hearing loss — the cochlear mean dose matters, with a goal of roughly ≤ 4 Gy for hearing preservation; after cavernous-sinus targets, cranial-nerve tolerance is generally favorable. Brainstem toxicity is constraint-limited (Dmax ≈ 12.5–15 Gy single fraction).